HPV-vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer epidemiology
- 130 Downloads
Cervical cancer incidence and mortality have decreased for the last 20 years in Austria; however, they remain relatively high in comparison to other European countries. Screening quality has been suboptimal. In this paper we aim to predict the population-wide long-term effects on cervical cancer morbidity and mortality after introducing an HPV vaccination for 12-year-old girls (and boys) in addition to current screening in comparison with screening only.
Health effects are predicted by a dynamic transmission model that was previously applied in the UK and the Norwegian contexts and validated for Austria. Outcomes analyzed are restricted to cervical cancer mortality and morbidity, which are predicted until 2060 assuming a coverage rate between 65% and 85%, a duration of protection between 10 years and lifelong, and a vaccine efficacy between 80% and 100% in the base case and best case, respectively. Additionally, implications for cancer epidemiology until 2088 are estimated.
Compared to screening only, screening plus vaccination of 12-year-old girls (and boys) would result in a median reduction of 10% (15%) fewer new cancer cases and 13% (20%) fewer cervical cancer deaths under best case assumptions over 52 years in the overall female population. In 2060, female population-based incidence and mortality would decrease by 27% and 43%, respectively, when vaccinating girls only and by 37% and 45% when additionally vaccinating boys. After 2060, a continuous further decrease in incidence and mortality can be expected with a maximum of minus 43% and 53%, respectively, in 2088 when vaccinating girls only.
Although a constant decrease in cervical cancer incidence and mortality is to be expected after introducing a population-wide HPV vaccination program in Austria, the reduction predicted by this model is lower than expected from clinical trials. This is due to several factors, such as low coverage rate and the long time horizon required for generating the maximum benefit of the vaccination in the overall population. In the context of limited resources, for further reducing cervical cancer in Austria, HPV vaccination programs need to be weighed against other public health alternatives such as improving screening quality.
KeywordsHPV vaccination Cervical carcinoma incidence Cervical carcinoma mortality Austria
The article is based on the results of the report entitled ‘Economic evaluation of HPV vaccination in Austria,’ which was funded by the Austrian Ministry of Health. We are grateful to the people from various Austrian institutions (Statistics Austria, Ministry of Health, Federation of the Austrian Social Insurance Institutions, Tyrolean Hospital Association) who provided the numerous data required, to the medical experts who supported us with their advice and expertise, and to our colleagues Claudia Wild and Philipp Radlberger who helped us with data collection and finalizing the analysis.
Conflict of Interest
The authors confirm that there are no relevant associations that might pose a conflict of interest.
- Barnabas RV, Garnett GP (2005) The potential public health impact of vaccines against human papillomavirus. In: Prendiville W, Davies P (eds) The health professionals HPV handbook. Taylor & Francis, AbingdonGoogle Scholar
- Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Health Technology Assessment in Health Care 24:10–19Google Scholar
- Bundesministerium für Gesundheit Familie und Jugend (BMGFJ) (2007) Impfstatistik. In. Bundesministerium für Gesundheit, Familie und Jugend; Abteilung Infektionskrankheiten, Seuchenbekämpfung und Krisenmanagement, WienGoogle Scholar
- Coste J, Cochand-Priollet B, de Cremoux P, Le Galés C, Cartier I, Molinié V, Labbé S, Vacher-Lavenu M-C, Vielh P (2003) Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. Br Med J 326:733CrossRefGoogle Scholar
- Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBCAN 2002 cancer incidence. mortality and prevalence worldwide. In: IARC CancerBase No. 5 version 2.0. IARC Press, LyonGoogle Scholar
- Hackl M (2007) Krebsstatistik. Sonderauswertung. In: Statistik Austria, WienGoogle Scholar
- Hauptverband der österreichischen Sozialversicherungsträger (2007) Datenerhebung Pap-Abstrich. In: Hauptverband der österreichischen Sozialversicherungsträger, WienGoogle Scholar
- National Board of Health, Danish Centre for Health Technology Assessement (2007) Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment. In: National Board of Health, Danish Centre for Health Technology Assessment, CopenhagenGoogle Scholar
- Neilson A, Freiesleben de Blasio B (2007) Economic evaluation of the human papillomavirus (HPV)-vaccination in Norway. In: Norwegian Knowledge Centre for the Health Services, OsloGoogle Scholar
- Nielsen E, Alfsen GC, Feiring B, Skjeldestad FE, Steen R, Saeterdal I (2007) Prophylactic vaccines against human papillomavirus. In: Norwegian Knowledge Centre for the Health Services, OsloGoogle Scholar
- Piso B, Wild C (2008) Rational vaccination policy - decision support. Review of international literature for ‘rational’ vaccination policies. In: Ludwig Boltzmann Institute for Health Technology Assessment, WienGoogle Scholar
- Statistik Austria (2007a) Bevölkerungsstatistik. Einzelauswertung. In: Statistik Austria, WienGoogle Scholar
- Statistik Austria (2007b) Jahrbuch der Gesundheitsstatistik 2005. In: Statistik Austria, WienGoogle Scholar
- Thiry N, Lambert M-L, Cleemput I, Huybrechts M, Neyt M, Hulstaert F, De Laet C (2007) HPV vaccination for the prevention of cervical cancer in Belgium: health technology assessment. In: Belgian Health Care Knowledge Centre (KCE), BrusselsGoogle Scholar